A tripeptide deletion in the R2 loop of the class C β-lactamase enzyme FOX-4 impairs cefoxitin hydrolysis and slightly increases susceptibility to β-lactamase inhibitors

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 6, 2010, Pages 1187-1194

  Mallo, Susana ^a   Pérez Llarena, Francisco J ^a   Kerff, Fréeric ^b   Soares, Nelson C ^a   Galleni, Moreno ^b   Bou, Germán ^a  

^a UNIVERSITY OF A CORUÑA   (Spain)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cephamycinase; Plasmid mediated AmpC; R2 loop; Structure function

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ASPARTIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CLAVULANIC ACID; CLOXACILLIN; GLYCINE; IMIPENEM; NITROCEFIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SERINE; SULBACTAM; TAZOBACTAM;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG HYDROLYSIS; ENZYME KINETICS; ENZYME PURIFICATION; ESCHERICHIA COLI; GENE DELETION; GENETIC VARIABILITY; HYDROLYSIS; HYPOTHESIS; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; SITE DIRECTED MUTAGENESIS; WILD TYPE;

AMINO ACID SEQUENCE; BETA-LACTAMASES; CEFOXITIN; ENZYME INHIBITORS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; SEQUENCE DELETION;

EID: 77953511839     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq115     Document Type: Article

References (21)

1. Beceiro A, Bou G. Class C β-lactamases: an increasing problem worldwide. Rev Med Microb 2004; 15: 141-52.
2. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980; 289: 321-31.
3. Barnaud G, Labia R, Raskine L et al. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol Lett 2001; 195: 185-90.
4. Pérez-Pérez F, Hanson ND. Detection of plasmid-mediated AmpC (-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40: 2153-62.
5. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly-and constitutively-expressed class I (-lactamases. J Antimicrob Chemother 1990; 25: 199-208.
6. Bush K, Macalintal C, Rasmussen BA et al. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother 1993; 37: 851-8.
7. Crichlow GV, Kuzin AP, Nukaga M et al. Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 1999; 38: 10256-61.
8. Sohn SG, Lee JJ, Sohn ES et al. Comment on: extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. J Antimicrob Chemother 2008; 61: 965-6.
9. Doi Y, Wachino J, Ishiguro M et al. Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. Antimicrob Agents Chemother 2004; 48: 2652-8.
10. Yamaguchi Y, Sato G, Yamagata Y et al. Structure of AmpC (-lactamase (AmpCD)froman Escherichia coli clinical isolate with a tripeptide deletion (Gly286-Ser287-Asp288) in the H10 helix. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009; 65: 540-3.
11. Mammeri H, Poirel L, Bemer P et al. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother 2004; 48: 716-20.
12. Kim JY, Jung HI, An YJ et al. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol Microbiol 2006; 60: 907-16.
13. Mammeri H, Poirel L, Nordmann P. Extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. Antimicrob Agents Chemother 2007; 60: 490-4.
14. CMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19. Antimicrob Agents Chemother 2006; 50: 534-41.
15. Barnaud G, Benzerara Y, Gravisse J et al. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother 2004; 48: 1040-2.
16. Bou G, Oliver A, Ojeda M et al. Molecular characterization of FOX-4, a new AmpC-type plasmid-mediated β-lactamase from an Escherichia coli strain isolated in Spain. Antimicrob Agents Chemother 2000; 44: 2549-53.
17. Ho SN, Hunt HD, Horton RM et al. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77:51-9.
18. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
19. Sirot D, Recule C, Chaibi EB et al. A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob Agents Chemother 1997; 41: 1322-5.
20. Mereghetti P, Ganadu ML, Papaleo E et al. Validation of protein models by a neural network approach. BMC Bioinformatics 2008; 9: 66.
21. Beadle BM, Shoichet BK. Structural basis for imipenem inhibition of class C β-lactamases. Antimicrob Agents Chemother 2002; 46: 3978-80.